Drug Contraindication

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 48 Experts worldwide ranked by ideXlab platform

Polard Elisabeth - One of the best experts on this subject based on the ideXlab platform.

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority \"ANSM\" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions \"Thesaurus\") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians mention of absolute IC with colchicine in the \"macrolide\" and \"pristinamycin\" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences.Bien que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) ait largement communiqué autour des facteurs de risque de surdosage en colchicine, des posologies recommandées et des conséquences, des cas de surdosages évitables potentiellement fatals continuent d’être rapportés en France. Utilisant le système national d’information inter-régimes de l’Assurance maladie sur la région Bretagne, nous avons quantifié la proportion de prescriptions présentant une contre-indication (CI) médicamenteuse absolue avec la colchicine (selon le Thésaurus des interactions médicamenteuses de l’ANSM) et son impact en termes d’hospitalisation. Entre 2013 et 2016, près de 77 000 patients (âge moyen, 66 ± 15 ans) ont eu au moins un remboursement d’une spécialité de colchicine (Colchimax®, Colchicine Opocalcium®), représentant près de 205 000 ordonnances. Les médecins généralistes étaient les principaux prescripteurs (93 %). Parmi les ordonnances, 0,5 % présentaient une CI absolue avec la colchcine : dans 51 % des cas avec la pristinamycine, suivi par l’azithromycine (15,6 %), la clarithromycine (15,2 %) et la roxithromycine (11,9 %). Dans les 15 jours suivant la prescription simultanée de colchicine et d’un médicament contre-indiqué, 53 séjours hospitaliers ont été recensés. Cependant, le seul diagnostic principal d’hospitalisation était insuffisant pour pouvoir conclure à l’absence d’un éventuel surdosage en colchicine. Sur la période d’étude, le Thésaurus comportait des incohérences sources de confusion pour les cliniciens : mention de la CI absolue avec la colchicine dans la section des macrolides et de la pristinamycine mais pas dans les sections des inhibiteurs puissants du CYP ni des molécules des classes des macrolides. Au total, très peu de prescriptions comportaient une CI absolue avec la colchicine. Une formation et information régulière des professionnels de santé restent primordiale pour limiter le risque de survenue de surdosage à la colchicine et rappeler les conséquences potentiellement fatales

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority "ANSM" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions "Thesaurus") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine: in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians: mention of absolute IC with colchicine in the "macrolide" and "pristinamycin" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences

Girard De Courtilles, Marion - One of the best experts on this subject based on the ideXlab platform.

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority \"ANSM\" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions \"Thesaurus\") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians mention of absolute IC with colchicine in the \"macrolide\" and \"pristinamycin\" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences.Bien que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) ait largement communiqué autour des facteurs de risque de surdosage en colchicine, des posologies recommandées et des conséquences, des cas de surdosages évitables potentiellement fatals continuent d’être rapportés en France. Utilisant le système national d’information inter-régimes de l’Assurance maladie sur la région Bretagne, nous avons quantifié la proportion de prescriptions présentant une contre-indication (CI) médicamenteuse absolue avec la colchicine (selon le Thésaurus des interactions médicamenteuses de l’ANSM) et son impact en termes d’hospitalisation. Entre 2013 et 2016, près de 77 000 patients (âge moyen, 66 ± 15 ans) ont eu au moins un remboursement d’une spécialité de colchicine (Colchimax®, Colchicine Opocalcium®), représentant près de 205 000 ordonnances. Les médecins généralistes étaient les principaux prescripteurs (93 %). Parmi les ordonnances, 0,5 % présentaient une CI absolue avec la colchcine : dans 51 % des cas avec la pristinamycine, suivi par l’azithromycine (15,6 %), la clarithromycine (15,2 %) et la roxithromycine (11,9 %). Dans les 15 jours suivant la prescription simultanée de colchicine et d’un médicament contre-indiqué, 53 séjours hospitaliers ont été recensés. Cependant, le seul diagnostic principal d’hospitalisation était insuffisant pour pouvoir conclure à l’absence d’un éventuel surdosage en colchicine. Sur la période d’étude, le Thésaurus comportait des incohérences sources de confusion pour les cliniciens : mention de la CI absolue avec la colchicine dans la section des macrolides et de la pristinamycine mais pas dans les sections des inhibiteurs puissants du CYP ni des molécules des classes des macrolides. Au total, très peu de prescriptions comportaient une CI absolue avec la colchicine. Une formation et information régulière des professionnels de santé restent primordiale pour limiter le risque de survenue de surdosage à la colchicine et rappeler les conséquences potentiellement fatales

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority "ANSM" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions "Thesaurus") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine: in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians: mention of absolute IC with colchicine in the "macrolide" and "pristinamycin" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences

Balusson Frédéric - One of the best experts on this subject based on the ideXlab platform.

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority \"ANSM\" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions \"Thesaurus\") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians mention of absolute IC with colchicine in the \"macrolide\" and \"pristinamycin\" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences.Bien que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) ait largement communiqué autour des facteurs de risque de surdosage en colchicine, des posologies recommandées et des conséquences, des cas de surdosages évitables potentiellement fatals continuent d’être rapportés en France. Utilisant le système national d’information inter-régimes de l’Assurance maladie sur la région Bretagne, nous avons quantifié la proportion de prescriptions présentant une contre-indication (CI) médicamenteuse absolue avec la colchicine (selon le Thésaurus des interactions médicamenteuses de l’ANSM) et son impact en termes d’hospitalisation. Entre 2013 et 2016, près de 77 000 patients (âge moyen, 66 ± 15 ans) ont eu au moins un remboursement d’une spécialité de colchicine (Colchimax®, Colchicine Opocalcium®), représentant près de 205 000 ordonnances. Les médecins généralistes étaient les principaux prescripteurs (93 %). Parmi les ordonnances, 0,5 % présentaient une CI absolue avec la colchcine : dans 51 % des cas avec la pristinamycine, suivi par l’azithromycine (15,6 %), la clarithromycine (15,2 %) et la roxithromycine (11,9 %). Dans les 15 jours suivant la prescription simultanée de colchicine et d’un médicament contre-indiqué, 53 séjours hospitaliers ont été recensés. Cependant, le seul diagnostic principal d’hospitalisation était insuffisant pour pouvoir conclure à l’absence d’un éventuel surdosage en colchicine. Sur la période d’étude, le Thésaurus comportait des incohérences sources de confusion pour les cliniciens : mention de la CI absolue avec la colchicine dans la section des macrolides et de la pristinamycine mais pas dans les sections des inhibiteurs puissants du CYP ni des molécules des classes des macrolides. Au total, très peu de prescriptions comportaient une CI absolue avec la colchicine. Une formation et information régulière des professionnels de santé restent primordiale pour limiter le risque de survenue de surdosage à la colchicine et rappeler les conséquences potentiellement fatales

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority "ANSM" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions "Thesaurus") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine: in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians: mention of absolute IC with colchicine in the "macrolide" and "pristinamycin" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences

Queric Claudine - One of the best experts on this subject based on the ideXlab platform.

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority \"ANSM\" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions \"Thesaurus\") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians mention of absolute IC with colchicine in the \"macrolide\" and \"pristinamycin\" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences.Bien que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) ait largement communiqué autour des facteurs de risque de surdosage en colchicine, des posologies recommandées et des conséquences, des cas de surdosages évitables potentiellement fatals continuent d’être rapportés en France. Utilisant le système national d’information inter-régimes de l’Assurance maladie sur la région Bretagne, nous avons quantifié la proportion de prescriptions présentant une contre-indication (CI) médicamenteuse absolue avec la colchicine (selon le Thésaurus des interactions médicamenteuses de l’ANSM) et son impact en termes d’hospitalisation. Entre 2013 et 2016, près de 77 000 patients (âge moyen, 66 ± 15 ans) ont eu au moins un remboursement d’une spécialité de colchicine (Colchimax®, Colchicine Opocalcium®), représentant près de 205 000 ordonnances. Les médecins généralistes étaient les principaux prescripteurs (93 %). Parmi les ordonnances, 0,5 % présentaient une CI absolue avec la colchcine : dans 51 % des cas avec la pristinamycine, suivi par l’azithromycine (15,6 %), la clarithromycine (15,2 %) et la roxithromycine (11,9 %). Dans les 15 jours suivant la prescription simultanée de colchicine et d’un médicament contre-indiqué, 53 séjours hospitaliers ont été recensés. Cependant, le seul diagnostic principal d’hospitalisation était insuffisant pour pouvoir conclure à l’absence d’un éventuel surdosage en colchicine. Sur la période d’étude, le Thésaurus comportait des incohérences sources de confusion pour les cliniciens : mention de la CI absolue avec la colchicine dans la section des macrolides et de la pristinamycine mais pas dans les sections des inhibiteurs puissants du CYP ni des molécules des classes des macrolides. Au total, très peu de prescriptions comportaient une CI absolue avec la colchicine. Une formation et information régulière des professionnels de santé restent primordiale pour limiter le risque de survenue de surdosage à la colchicine et rappeler les conséquences potentiellement fatales

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority "ANSM" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions "Thesaurus") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine: in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians: mention of absolute IC with colchicine in the "macrolide" and "pristinamycin" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences

Bouric Stéphanie - One of the best experts on this subject based on the ideXlab platform.

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority \"ANSM\" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions \"Thesaurus\") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians mention of absolute IC with colchicine in the \"macrolide\" and \"pristinamycin\" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences.Bien que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) ait largement communiqué autour des facteurs de risque de surdosage en colchicine, des posologies recommandées et des conséquences, des cas de surdosages évitables potentiellement fatals continuent d’être rapportés en France. Utilisant le système national d’information inter-régimes de l’Assurance maladie sur la région Bretagne, nous avons quantifié la proportion de prescriptions présentant une contre-indication (CI) médicamenteuse absolue avec la colchicine (selon le Thésaurus des interactions médicamenteuses de l’ANSM) et son impact en termes d’hospitalisation. Entre 2013 et 2016, près de 77 000 patients (âge moyen, 66 ± 15 ans) ont eu au moins un remboursement d’une spécialité de colchicine (Colchimax®, Colchicine Opocalcium®), représentant près de 205 000 ordonnances. Les médecins généralistes étaient les principaux prescripteurs (93 %). Parmi les ordonnances, 0,5 % présentaient une CI absolue avec la colchcine : dans 51 % des cas avec la pristinamycine, suivi par l’azithromycine (15,6 %), la clarithromycine (15,2 %) et la roxithromycine (11,9 %). Dans les 15 jours suivant la prescription simultanée de colchicine et d’un médicament contre-indiqué, 53 séjours hospitaliers ont été recensés. Cependant, le seul diagnostic principal d’hospitalisation était insuffisant pour pouvoir conclure à l’absence d’un éventuel surdosage en colchicine. Sur la période d’étude, le Thésaurus comportait des incohérences sources de confusion pour les cliniciens : mention de la CI absolue avec la colchicine dans la section des macrolides et de la pristinamycine mais pas dans les sections des inhibiteurs puissants du CYP ni des molécules des classes des macrolides. Au total, très peu de prescriptions comportaient une CI absolue avec la colchicine. Une formation et information régulière des professionnels de santé restent primordiale pour limiter le risque de survenue de surdosage à la colchicine et rappeler les conséquences potentiellement fatales

  • Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie
    'Elsevier BV', 2020
    Co-Authors: Girard De Courtilles, Marion, Balusson Frédéric, Queric Claudine, Bouric Stéphanie, Carlhant-kowalski Dominique, Scailteux Lucie-marie, Polard Elisabeth
    Abstract:

    National audienceAlthough the French Health Authority "ANSM" widely informed healthcare professionals about the risk factors for colchicine overdose, its impact and suitable dosages, cases of potentially fatal preventable overdose continue to be reported in France. Using the French National Health Insurance of the Brittany area, we quantified the proportion of prescriptions presenting an absolute Drug Contraindication (CI) to colchicine (according to the ANSM Drug Interactions "Thesaurus") and its impact in terms of hospitalisation. Between 2013 and 2016, nearly 77,000 patients (mean age, 66±15 years) were reimbursed for at least one colchicine-based Drug (Colchimax®, Colchicine Opocalcium®), representing nearly 205,000 prescriptions. General practitioners were the main prescribers (93%). Among the prescriptions, 0.5% had absolute IC with colchicine: in 51% of cases with pristinamycin, followed by azithromycin (15.6%), clarithromycin (15.2%) and roxithromycin (11.9%). In the 15 days following the simultaneous prescription of colchicine and a contraindicated Drug, 53 hospital stays were recorded. However, using only the primary diagnosis of hospitalization was not sufficiently relevant to conclude that there was no potential overdose of colchicine. Over the study period, the Thesaurus contained inconsistencies that confused clinicians: mention of absolute IC with colchicine in the "macrolide" and "pristinamycin" sections but not in the sections of 'potent CYP inhibitors' or macrolide class molecules. Overall, very few prescriptions included absolute IC with colchicine. Regular training and information of healthcare professionals remains essential to limit the risk of colchicine overdose and to remind them of the potentially fatal consequences

Drug Contraindication - 15 days free trial to Access Experts & Abstracts